1.50
1.96%
-0.03
Rockwell Medical Inc stock is currently priced at $1.50, with a 24-hour trading volume of 14,531.
It has seen a -1.96% decreased in the last 24 hours and a -12.28% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.53 pivot point. If it approaches the $1.48 support level, significant changes may occur.
Previous Close:
$1.53
Open:
$1.54
24h Volume:
14,531
Market Cap:
$44.05M
Revenue:
$83.61M
Net Income/Loss:
$-8.44M
P/E Ratio:
-1.7045
EPS:
-0.88
Net Cash Flow:
$-9.70M
1W Performance:
+1.35%
1M Performance:
-12.28%
6M Performance:
-13.79%
1Y Performance:
-32.13%
Rockwell Medical Inc Stock (RMTI) Company Profile
Name
Rockwell Medical Inc
Sector
Phone
248 960 9009
Address
30142 South Wixom road, Suite 501, Wixom, NJ
Rockwell Medical Inc Stock (RMTI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-24-19 | Initiated | Piper Jaffray | Overweight |
May-13-19 | Initiated | H.C. Wainwright | Buy |
Nov-08-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
Mar-01-16 | Downgrade | Stifel | Buy → Hold |
Aug-13-15 | Initiated | Morgan Stanley | Underweight |
Jan-27-15 | Reiterated | Oppenheimer | Outperform |
Jan-07-15 | Initiated | Oppenheimer | Outperform |
Aug-14-14 | Initiated | FBR Capital | Underperform |
Dec-19-13 | Initiated | Chardan Capital Markets | Buy |
Nov-06-13 | Reiterated | Summer Street Research | Buy |
Sep-05-13 | Reiterated | Summer Street Research | Buy |
Aug-02-13 | Reiterated | Summer Street Research | Buy |
Apr-11-12 | Initiated | Summer Street Research | Buy |
Mar-12-12 | Initiated | Stifel Nicolaus | Buy |
Jan-03-12 | Initiated | Canaccord Genuity | Buy |
Dec-10-09 | Initiated | JMP Securities | Mkt Outperform |
Oct-12-09 | Initiated | Wedbush Morgan | Outperform |
View All
Rockwell Medical Inc Stock (RMTI) Latest News
Rockwell Medical (RMTI) Increases Despite Market Slip: Here's What You Need to Know
Zacks Investment Research
Rockwell Medical (RMTI) Q4 Earnings and Revenues Beat Estimates
Zacks Investment Research
Rockwell Medical (RMTI) Rises As Market Takes a Dip: Key Facts
Zacks Investment Research
Rockwell Medical (RMTI) Ascends While Market Falls: Some Facts to Note
Zacks Investment Research
Rockwell Medical (RMTI) Flat As Market Gains: What You Should Know
Zacks Investment Research
Why Rockwell Medical (RMTI) Dipped More Than Broader Market Today
Zacks Investment Research
Rockwell Medical Inc Stock (RMTI) Financials Data
Rockwell Medical Inc (RMTI) Revenue 2024
RMTI reported a revenue (TTM) of $83.61 million for the quarter ending December 31, 2023, a +14.84% rise year-over-year.
Rockwell Medical Inc (RMTI) Net Income 2024
RMTI net income (TTM) was -$8.44 million for the quarter ending December 31, 2023, a +54.83% increase year-over-year.
Rockwell Medical Inc (RMTI) Cash Flow 2024
RMTI recorded a free cash flow (TTM) of -$9.70 million for the quarter ending December 31, 2023, a +43.66% increase year-over-year.
Rockwell Medical Inc (RMTI) Earnings per Share 2024
RMTI earnings per share (TTM) was -$0.40 for the quarter ending December 31, 2023, a +76.47% growth year-over-year.
About Rockwell Medical Inc
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Cap:
|
Volume (24h):